Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study

doi:10.3748/wjg.v28.i15.1574

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 15

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4167)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

175

WORD

116

HTML

1737

Figures (1-5)

205

Tables (1-4)

190

Sum=2423

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

309

Download

472

Sum=781

Publishing Process of This Article

Item

Count

Browse

296

Download

667

Sum=963

Apr 21, 2022 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 21, 2022; 28(15): 1574-1587
Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1574

Table 4 Individual characteristics of patients receiving multimodality therapy for recurrent intrahepatic cholangiocarcinoma

Clinical features					Pathological characteristics				Recurrent		Survival
Case	Age (yr)	Sex	Hepatitis	Surgery	Lymph node metastasis	Tumour size (cm)	Tumour number	Histological grade	Recurrent site	Treatment	DFS (mo)	SAR (mo)	Outcome
1	62	M	HBV	ERH	Yes	12	1	MD	Liver + lymph node	TACE + GEMOX	4	3	Dead
2	48	M	HBV	ERH	None	8	1	MD	Liver	TACE + GEMOX	11	13	Dead
3	40	M	HBV	ERH	None	5	2	MD	Liver + lymph node + bone	TACE + GEMOX	2	5	Dead
4	53	M	None	LH	None	11	1	MD	Liver + lymph node	RFA + TACE + SOX	6	6	Alive
5	44	M	HBV	RH	None	14	1	MD	Liver + bone	RFA + FOLFOX-4	3	2	Dead
6	64	M	None	ERH	Yes	22	1	MD	Liver	RFA + PD-1 + TKI	4	1	Alive

DFS: Disease-free survival; SAR: Survival after recurrence; M: Male; HBV: Hepatitis B virus; ERH: Extended right hepatectomy; LH: Left hepatectomy; RH: Right hepatectomy; MD: Moderate differentiated; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; GEMOX: Gemcitabine + oxaliplatin; FOLFOX-4: Fluorouracil + calcium folate + oxaliplatin; SOX: Tegafur + oxaliplatin; PD-1: Programmed death-1 inhibitor; TKI: Tyrosine kinase inhibitor.

Citation: Yuan ZB, Fang HB, Feng QK, Li T, Li J. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study. World J Gastroenterol 2022; 28(15): 1574-1587
URL: https://www.wjgnet.com/1007-9327/full/v28/i15/1574.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i15.1574